MassDevice.com looked at some of the most talked-about medical device companies, based on trends in U.S. Google searches for the last 30 days.
Last month’s headlines were entirely dominated by news of the mega-merger between Medtronic (NYSE:MDT) and Covidien (NYSE:COV), so it’s no surprise that the companies were firmly entrenched atop June’s top 5 for internet chatter. With a deal as game-changing as this one, there was hardly room for anyone else to issue news, but a few other companies managed to garner some interest anyway.
Allergan’s (NYSE:AGN) ongoing saga with activist investors and would-be acquirers landed the company on the list for the 1st time, taking 3rd place as it fights off Valeant Pharmaceuticals, Bill Ackman’s Pershing Capital Management and new player Paulson & Co.
Boston Scientific (NYSE:BSX) and St. Jude Medical (NYSE:STJ) tied to round out the top 5. Although they had a hard time grabbing headlines around the tumult in the industry, Boston Scientific got some attention for a delayed time line for its Watchman anti-stroke device and St. Jude closed its acquisition of CardioMEMS.
Medtronic (and frequently Covidien)
- EXCLUSIVE: Medtronic’s strategy guru on the $43B Covidien buy
- Study: Medtronic’s Reveal XT bests conventional follow-up
- Microsoft and Becton Dickinson team up in Israel
- Report: Shareholders pick up the tab when Medtronic skirts taxes
- Medtronic-Covidien merger will rival JNJ medical device operations
- Seven questions raised by Medtronic’s $43B Covidien acquisition
- Medtronic taps strategy exec to lead Covidien integration
- Does the Medtronic-Covidien mega-merger leave startups in the cold?
- Supreme Court refuses to hear Medtronic’s pain pump lawsuit appeal
- Medtronic got hacked, company reveals
- Medtronic’s medical device tax bill was $112M
- Medtronic, Covidien merger: Good or bad for medtech innovation?
- Cardiostim 2014: Medtronic treats 1st patients with tiny Micra pacemaker, Sorin touts ‘SafeR’ pacing
- Stryker alleges Medtronic colluded with patent troll for Kyphon IP
- Medtronic acquires Covidien in a $43 billion deal
- Blockbuster: Medtronic in $43B deal to acquire Covidien
- Medtronic’s AdaptivCRT implants chop follow-up care in half, study finds
- Seven questions raised by Medtronic’s $43B Covidien acquisition
- Medtronic, Covidien merger: Mass. Gov. Deval Patrick says he’s had no contact with either company
- Medtronic-Covidien: What does it mean for medtech?
- Analysis: What does the union of Medtronic and Covidien mean for medtech?
- Medtronic puts $17M into community chronic disease program
- Op-ed: Medtronic/Covidien deal good for patients, Minnesota
- Medtronic buyout holds $80M in golden parachutes for Covidien execs
- Medtronic’s OUS move becomes a political football
- Diabetes: Medtronic and Sanofi ally on new drug-device combinations
- Analysis: What does the union of Medtronic and Covidien mean for medtech?
- Former Medtronic CEO Bill George bullish on Medtronic/Covidien deal
- Blockbuster: Medtronic in $43B deal to acquire Covidien
- FLASH: FDA approves Medtronic’s CoreValve for high-risk patients
- Medtronic files final PMA module for In.Pact Admiral drug-eluting balloon
- Independent legal panel rejects Infuse allegations in Medtronic shareholder suits
- Medtronic confirms Corventis buy, expects to close this month
- Medtronic, Johnson & Johnson park billions in offshore accounts
- Ishrak: Medtronic needs to get smart about emerging markets
- Medtronic mum on potential Smith & Nephew buy
- What if Stryker bought Smith & Nephew?
- Report: Is Medtronic looking to buy Smith & Nephew?
- Medtronic: Solicitor General got it wrong on preemption
- Diabetes: Medtronic wins CE Mark for MiniMed Duo
- Medtronic wants candidates for $20k patient innovator award
- Humana levels racketeering lawsuit against Medtronic over Infuse bone graft
Covidien
- Covidien’s next-gen Pipeline embolization lands in Europe
- Covidien levels another lawsuit at Ethicon Endo over ultrasound shears
- Covidien guidewire recalled amid damage reports
- Covidien lands FDA win for neurovascular micro catheter
- Covidien’s 3-in-1 Nellcor monitoring gets E.U. approval
Allergan
- Allergan reveals FDA win, lobbies to keep Valeant out
- Report: Another activist investor pressures Allergan to sell
- Allergan urges shareholders to reject Valeant’s $52B hostile takeover bid
- Valeant goes hostile in bid for Allergan
- Ackman takes Allergan to court to defend against ‘poison pill’
- Allergan board members unanimously reject Valeant’s $53B offer
- Allergan proxy war gets ugly as Valeant aims to unseat the board
Boston Scientific
- FDA wants another panel hearing on Boston Scientific’s Watchman anti-stroke device
- UPDATE: Boston Scientific touts Vercise DBS for Parkinson’s
- Pacemaker inventor’s family’s $570M suit against Boston Scientific bounces back to state court
- Boston Scientific launches TAVI registry study for Lotus heart valve
St. Jude Medical
